|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM225862530 |
| 003 |
DE-627 |
| 005 |
20231224070128.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2013.02.005
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0753.xml
|
| 035 |
|
|
|a (DE-627)NLM225862530
|
| 035 |
|
|
|a (NLM)23499139
|
| 035 |
|
|
|a (PII)S1521-6616(13)00040-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Long, S Alice
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a IL-2 therapy in type 1 diabetes
|b "Trials" and tribulations
|
| 264 |
|
1 |
|c 2013
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.12.2013
|
| 500 |
|
|
|a Date Revised 21.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2013 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a IL-2 facilitates immunity or tolerance depending on its availability. In model systems, it is well established that low dose IL-2 promotes selective expansion of regulatory T cells (Treg), an IL-2 responsive cell type known to control autoimmunity. Moreover, many autoimmune diseases are marked by defects in Treg and/or IL-2/IL-2 receptor signaling. Thus, patients with immune-mediated diseases were treated with IL-2 with the goal of increasing Treg and controlling autoimmunity. In graft versus host disease, HCV-induced vasculitis and type 1 diabetes (T1D), Treg numbers increased with IL-2 therapy. Yet there was no relationship between Treg number and clinical outcome. In fact, in T1D subjects treated with rapamycin and IL-2 therapy there was no measureable clinical benefit. In this review, we compare results from IL-2 treatment of patients with immune-mediated diseases, discuss possible mechanisms of IL-2 treatment and suggest future directions for use of IL-2 therapy in T1D
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Clinical trials;
|
| 650 |
|
4 |
|a GVHD
|
| 650 |
|
4 |
|a GVHD;
|
| 650 |
|
4 |
|a HCV-induced vasculitis
|
| 650 |
|
4 |
|a IL-2 receptor
|
| 650 |
|
4 |
|a IL-2;
|
| 650 |
|
4 |
|a IL2R
|
| 650 |
|
4 |
|a MMTT
|
| 650 |
|
4 |
|a Regulatory T cells
|
| 650 |
|
4 |
|a Regulatory T cells;
|
| 650 |
|
4 |
|a T1D
|
| 650 |
|
4 |
|a Teff
|
| 650 |
|
4 |
|a Treg
|
| 650 |
|
4 |
|a Type 1 diabetes;
|
| 650 |
|
4 |
|a effector T cells
|
| 650 |
|
4 |
|a graft versus host diseases
|
| 650 |
|
4 |
|a mixed meal tolerance test
|
| 650 |
|
4 |
|a type 1 diabetes
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-2
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Interleukin-2
|2 NLM
|
| 700 |
1 |
|
|a Buckner, Jane H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Greenbaum, Carla J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 149(2013), 3 vom: 02. Dez., Seite 324-31
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:149
|g year:2013
|g number:3
|g day:02
|g month:12
|g pages:324-31
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2013.02.005
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 149
|j 2013
|e 3
|b 02
|c 12
|h 324-31
|